Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Nouscom logo — company profile

Nouscom

Founded 2015 Switzerland Switzerland 57 employees Series C Total: $128.50M Biotechnology, Health Care +1

General Information

Company Name Nouscom
Founded Year 2015
Location Switzerland Switzerland
Employees 57
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Nouscom . To contact Nouscom , visit nouscom.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Nouscom compare?

A PDF of Nouscom and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Nouscom soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Nouscom

Nouscom is a biotech startup founded in 2015 and headquartered in Switzerland. The company is focused on developing highly effective immunotherapeutics targeting cancerous cells. Its last funding round, a €75.80M Series C investment on 21 March 2024, saw participation from a diverse group of investors including Bpifrance, 5AM Ventures, Life Science Partners, Versant Ventures, Andera Partner, Indaco Venture Partners, MERL Ventures Fund, Panakes Partners, Revelation Partners, and XGEN Venture. Nouscom operates in the biotechnology and health care industries, and its innovative approach to immunotherapy positions the company at the forefront of the fight against cancer.

Business keywords: biotech, startup, immunotherapeutics, cancer treatment, oncology, biomedical, biopharmaceuticals, cell targeting, cancer research, innovation

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series C €7.00M 1
Angelini Ventures
Angelini Ventures
21 Mar 2024
Series C €67.50M 9
5AM Ventures Versant Ventures Andera Partner
5AM Ventures, Versant Ventures +7
14 Nov 2023
Series B €42.00M -
06 Nov 2017
Series A €12.00M -
17 May 2016

Nouscom Alternatives & Competitors

View All Alternatives
Nouscom vs
OncoPep, Inc.
OncoPep, Inc. United States

To develop and commercialize targeted immuno-therapeutics which prevent the progression of cancer an...

Series D
4 employees
Biotechnology, Health Care
Compare Nouscom vs OncoPep, Inc.
Nouscom vs
Rebirthel Co.,Ltd.
Rebirthel Co.,Ltd. Japan

An independent biocompany, developing cellular immunotherapies for cancer, based on Kyoto.

Venture round
3 employees
Biotechnology, Health Care
Compare Nouscom vs Rebirthel Co.,Ltd.
Nouscom vs
CTMC - a joint venture between Resilience + MD Anderson Cancer Center
CTMC - a joint venture between Resilience + MD Anderson Cancer Center United States

We accelerate development + manufacturing of innovative cell therapies to cure cancer.

87 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Nouscom

Nouscom is a private clinical stage immuno-oncology company developing off-the-shelf and personalized cancer immunotherapies using proprietary viral vectors with demonstrated high immunogenicity in patients. Nouscom’s clinical pipeline includes NOUS-209, an off-the-shelf cancer immunotherapy assess...
Nouscom was founded in 2015.
Nouscom is headquartered in Switzerland.
Nouscom operates in Biotechnology, Health Care and Health and Wellness. Its work centres on biotech, startup, immunotherapeutics and cancer treatment.
Nouscom has approximately 57 employees.
Nouscom has completed 4 funding rounds, raising a total of $128.50M. The latest funding stage is Series C.
Top alternatives and competitors to Nouscom include OncoPep, Inc., Rebirthel Co.,Ltd., CTMC - a joint venture between Resilience + MD Anderson Cancer Center, Prescient Therapeutics, Genus Oncology LLC. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Nouscom and OncoPep, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Nouscom , https://bouncewatch.com/company/nouscom, updated 29 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout